Breast Cancer
Current Clinical Trials
Curie Research by Curie Oncology
Clinical Trial – Breast Cancer
| Protocol Name / No. | Protocol Title | Principal Investigator |
|---|---|---|
| ELEGANT | Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study NCT number: https://clinicaltrials.gov/study/NCT06492616 | Dr Lynette Ngo |
| TROPION-Breast05 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab paclitaxel or Gemcitabine + Carboplatin) in combination with Pembrolizumab in Patients with PD L1 positive Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer NCT number: https://clinicaltrials.gov/study/NCT06103864 | Dr Lynette Ngo |
| RLY-2608-102 | A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor NCT number: https://clinicaltrials.gov/study/NCT06982521 | Dr Lynette Ngo |
| ASPEN-09-03 | A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer NCT number: https://clinicaltrials.gov/study/NCT07007559 | Dr Lynette Ngo |